Genta, Inc. (GNTA) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genta, Inc. (GNTA)

GNTA 2.300

+0.4%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John Nobrega who started this subject	4/20/2004 3:01:13 PM
From: bob zagorin	Read Replies (1) of 1870

from briefing.com 8:47AM Genta and Aventis announce expanded access program for Genasense (GNTA) 12.3: Genta (GNTA) and Aventis (AVE) today announced the availability of Genasense Injection for use in combination with dacarbazine through an Expanded Access Program for eligible patients in the U.S. with advanced melanoma who have not previously received chemotherapy. Genasense in combination with dacarbazine has been granted priority review by the U.S. Food and Drug Administration for potential approval for the treatment of advanced melanoma. According to the press release, expanded access programs are designed to make investigational agents available at the earliest opportunity for the treatment of patients with diseases for which no comparable or satisfactory alternative drug is available.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next